Many men with Peyronie’s disease are embarrassed and choose to suffer in silence rather than get help. Peyronie’s disease can be a physically and psychologically devastating. This case report presents a successful correction of penile curvature using platelet rich plasma (PRP) treatment in an office setting.
CarrieriMPSerrainoDPalmiottoFNucciGSassoF.A case-control study on risk factors for Peyronie’s disease. J Clin Epidemiol. 1998;51(6):511-515. doi:10.1016/S0895-4356(98)00015-8.
4.
NelsonCJMulhallJP.Psychological impact of Peyronie’s disease: a review. J Sex Med. 2013;10(3):653-660. doi:10.1111/j.1743-6109.2012.02999.x.
5.
EricCGeralbB.Penile traction therapy and Peyronie’s disease: a state of art review of the current literature. Ther Adv Urol. 2013;5(2):59-65. doi:10.1177/1756287212454932.
6.
LevineLA.Review of current nonsurgical management of Peyronie’s disease. Int J Impot Res. 2003;15(suppl 5):S113-S120. doi:10.1038/sj.ijir.3901084.
7.
MynderseLAMongaM.Oral therapy for Peyronie’s disease. Int J Impot Res. 2002;14(5):340-344. doi:10.1038/sj.ijir.3900869.
8.
Prieto CastroRMLeva VallejoMERegueiro LopezJCAnglada CuradoFJAlvarez KindelanJRequena TapiaMJ.Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522-524. doi:10.1046/j.1464-410X.2003.04134.x.
9.
WeidnerWHauckEWSchnitkerJ.Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-535; discussion 535-536. doi:10.1016/j.eururo.2004.12.022.
10.
SafarinejadMRAsgariMAHosseiniSYDadkhahF.A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2010;106(2):240-248. doi:10.1111/j.1464-410X.2009.09041.x.
11.
SafarinejadMR.Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298-309. doi:10.1038/ijir.2010.20.
12.
HellstromWJKendirciMMaternR, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394-398. doi:10.1016/S0022-5347(06)00517-9.
13.
FDA approves first drug treatment for Peyronie’s disease. [FDA news release]. Silver Spring, MD: U.S. Food and Drug Administration. December6, 2013.
